Case of anti-SRP-positive patient with IIM, who developed inflammatory cardiomyopathy was described [20]

Case of anti-SRP-positive patient with IIM, who developed inflammatory cardiomyopathy was described [20]. IIM group than in healthy subjects (median sST2 in IIM 26.51 vs in healthy controls 21.39; MannCWhitney test. Associations between clinical symptoms, comorbidities or ANA subtypes with sST2 and IL-33 concentrations were evaluated with MannCWhitney assessments (for symptoms and comorbidities only if they were present in at least four patients). Linear regressions were performed to evaluate the influence of the laboratory parameters, myalgia, muscle weakness, fatigue, tolerance of physical activity and degree of disability on sST2 and IL-33 levels. The procedures followed were in accordance with the ethical standards and were approved by the responsible bioethical committee on human experimentation (Bioethical Committee of the Medical University of Lodz, Poland, date of approval: 15.05.2018, reference number: Rabbit Polyclonal to IRS-1 (phospho-Ser612) RNN/173/18/KE). All patients gave written, informed consent for participation in the study. Results Clinical characteristics of the patients enrolled for the study as well results of laboratory assessments are presented in Table ?Table1.1. Half of the patients declared exertional dyspnoea or episodes of chest pounding/irregular heartbeat occurring currently or in the past after the diagnosis of IIM. Most common comorbidities in patients with IIM included hypertension, thyroid disorders, interstitial lung disease and hypercholesterolemia/atherosclerosis. 10 patients filled in the Short 2-page Health Assessment Questionnaire. According to SDI, 30% fulfilled the criteria of mild-to-moderate disability, 40% of moderate-to-severe disability and 30% of severe-to-very severe disability. Table 1 Clinical characteristics of the patients and healthy controls recruited for the study (%)]?Arthralgia7 (43.75)CC?Dysphagia6 (37.5)CC?Dysphonia7 (43.75)CCC?Erythema5 (31.25)CC?Gottron papules/sign3 (18.75)CC?Raynaud phenomenon2 (12.5)CC?Mechanics hands3 (18.75)CC?Dyspnoea at rest4 (25.00)CC?Exertional dyspnoea8 (50.00)CC?Chest pain2 (12.5)CC?Irregular heartbeat, chest Furilazole pounding8 (50.00)CC?Dry cough3 (18.75)CC?Productive cough3 (18.75)CC?Fever2 (12.5)CCVAS 0C10?Myalgia6.25; 0C10 ((%)]?Hypertension9 (56.25)CC?Thyroid disorders7 (43.75)CC?Interstitial lung disease/unspecified interstitial lesions7 (43.75)CC?Hypercholesterolemia, atherosclerosis5 (31.25)CC?Arrhythmia3 (18.75)CC Open in a separate window (%)]?Jo-18 (50.00)CC?Ro-5210 (62.50)CC?SRP3 (18.75)CC?Pm-Scl4 (25.00)CC?AMA-M23 (18.75)CC24?h ECG holter monitoring [(%)]? ?2000 supraventricular extrasystoles2 (22.23) (idiopathic inflammatory myopathy, number of patients, female, male, antinuclear antibodies, visual analogue scale All the 16 patients were ANA-positive, specific autoantibodies were detected in 15 patients (93.75%). 11 out of 16 patients included in the study group had myositis-specific autoantibodies, four patients had only myositis-associated autoantibodies. In one patient (ANA positive), no specific autoantibodies were detected. The most common subtype of ANA was anti-Ro52 in 62.50% of patients, followed by anti-Jo1 in 50% of cases, anti-PM-Scl in 25%, anti-SRP in 18.75% and AMA-M2 in 18.75% (Table ?(Table1).1). Single cases of anti-Ku, anti-HI and anti-centromere antibodies were detected. Mean values of complete blood count, ESR and CRP in patients remained within normal limit, whereas levels of CK, CK-MB, myoglobin, NT-proBNP, AST and ALT were elevated (Table ?(Table1).1). Noteworthy, 87% out of 15 patients with IIM presented elevated levels of troponin T, whereas troponin I was increased only in 20% of them (Table ?(Table11). Concentrations of sST2 in sera ranged from 13.12 to 68.67?ng/ml in patients with IIM and from 15.24 to 32.40?ng/ml in healthy controls. Concentrations of sST2 were significantly higher in IIM group than in healthy subjects (median sST2 in IIM 26.51?ng/ml vs median sST2 in healthy controls 21.39; em p /em ?=?0.03). Concentrations of IL-33 in sera ranged from below the detection limit to 956.35?pg/ml. In half of the patients with IIM and half of the control group concentrations of IL-33 did not exceed the detection limit of 15.6?pg/ml. No significant difference was observed in serum concentrations of IL-33 between patients with Furilazole IIM and healthy controls (respectively,?median 0.4019; ?15.6 to 956.35 in IIM group vs median?1.5404; ?15.6 to 1051.64 in control group; em p /em ?=?0.8). No significant difference was observed in concentrations of Furilazole sST2 and IL-33 between patients with and without dyspnoea, chest pounding/irregular heartbeat and remaining clinical symptoms such as arthralgia, dysphonia, dysphagia, erythema. Comorbidities, degree of myalgia, muscle weakness, fatigue and tolerance of physical activity were neither associated with significantly higher concentrations of sST2 or IL-33. Anti-SRP-positive patients presented significantly higher concentrations of sST2 as compared to anti-SRP-negative patients (Fig.?1, mean value of 52.49??16.57?ng/ml in anti-SRP-positive patients vs mean value of 28.33??11.32?ng/ml in Furilazole anti-SRP-negative patients; em p /em ?=?0.04). In contrast, in patients with anti-Ro52 antibodies,.